Virus-Mimicking Nanoparticles Enable Oral Insulin Delivery by Penetrating Gut Barriers

Virus-mimicking mesoporous silica nanoparticles coated with the cell-penetrating peptide KLPVM and glutaric anhydride achieved near-neutral surface charge (ζ-potential -0.49 mV), enabling them to penetrate the intestinal mucus layer without binding to mucin — unlike positively charged nanoparticles (ζ-potential +35.00 mV). Transepithelial transport was 2.4-fold higher than unmodified nanoparticles. In diabetic rats, insulin loaded into these nanoparticles reduced blood glucose by nearly 50%, with 2.1-fold higher bioavailability than insulin administered directly into the jejunum. No significant toxicity was observed in preliminary in vitro or in vivo studies.

Researchers fabricated mesoporous silica nanoparticles with 6 nm pores for insulin loading, then coated them with the cationic cell-penetrating peptide KLPVM and anionic glutaric anhydride to create a near-neutral surface. Mucus penetration was tested against mucin in vitro. Intestinal transport was measured using Caco-2/E12 cell co-culture models. Endocytosis pathways were characterized. Insulin stability was confirmed under simulated intestinal conditions. In vivo testing in diabetic rats measured blood glucose reduction and insulin bioavailability compared to direct jejunal insulin administration.

Insulin and most peptide drugs cannot currently be taken orally because they are destroyed in the stomach and cannot pass through the intestinal mucus and epithelial barriers. This virus-mimicking approach solves both problems simultaneously — using a neutral, hydrophilic surface to slip through mucus (like viruses do) and a cell-penetrating peptide to cross the intestinal wall. Success here could transform diabetes management and open the door for oral delivery of many other peptide therapeutics.

Oral delivery of peptide and protein drugs is one of the biggest unsolved challenges in pharmaceutical science. Many important medications — insulin, GLP-1 agonists, growth hormone — require injection because they can't survive the gastrointestinal tract. This virus-mimicking approach is part of a broader effort to develop oral peptide delivery technologies that could transform how these medications are administered, improving patient compliance and quality of life.

While the diabetic rat results are promising, animal models do not always predict human responses. The study used relatively small numbers of animals and did not assess long-term safety or repeated dosing. The manufacturing scalability of these nanoparticles for commercial production was not addressed. Human clinical trials would be needed to confirm efficacy and safety.